• Alzheimer's Boom or Bust

  • 2022/10/14
  • 再生時間： 1 時間 5 分
  • ポッドキャスト

Alzheimer's Boom or Bust

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.

    email: econrxpodcast@gmail.com

    Twitter/Instagram: @EconRx

    LinkedIn: www.linkedin.com/company/econrx

    Website: https://econrx.libsyn.com/
    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/
続きを読む 一部表示

Alzheimer's Boom or Bustに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。